Federal Jury Orders Gilead To Pay Merck $200 Million In Hepa C Drug Patent Dispute Merck is set to receive $200 million in damages from Gilead Sciences as federal jury decides on patent dispute. Merck claims they should be credited for liver therapy breakthrough. by Catherine Cabral-Isabedra
Healthy Living/Wellness Gilead Fights For Hepa C Drug Patents: Activists Concerned About Drug Accessibility by Dianne Depra
Healthy Living/Wellness Expensive Sovaldi drug for hepatitis C still most cost-effective choice for U.S. prisons: Study by Dianne Depra
Healthy Living/Wellness Study shows promising hep C cure for patients co-infected with HIV by Tina Shah